Cantor Fitzgerald raises Abbvie stock price target to $215 on strong Skyrizi performance

Abbvie (ABBV) reported robust Q2 2025 results, exceeding revenue and EPS forecasts primarily due to strong Skyrizi sales, prompting Cantor Fitzgerald to raise its price target to $215 and maintain an Overweight rating. The company subsequently raised its full-year guidance, while analysts, including Piper Sandler, view Abbvie as a compelling growth play with strong immunology drug performance and strategic manufacturing investments, positioning it favorably amidst sector dynamics.

Analysis

AbbVie (ABBV) demonstrated significant operational strength in its second-quarter 2025 results, delivering an earnings beat with an EPS of $2.97 on revenue of $15.4 billion, surpassing forecasts of $2.96 and $14.99 billion respectively. This outperformance was primarily driven by robust sales from its immunology drug Skyrizi, which exceeded high market expectations and prompted the company to raise its full-year top-line guidance. The positive results have been met with favorable analyst actions, including a price target increase by Cantor Fitzgerald to $215.00 from $210.00 and an initiation of coverage with an Overweight rating by Piper Sandler. The consensus outlook is strengthening, with 14 analysts revising earnings estimates upward. Strategically, AbbVie is viewed as a compelling growth alternative with limited near-term risk, bolstered by a $195 million investment in manufacturing and a promising pipeline asset, ABBV-295, which has a phase 1 data read-out expected early next year.

Key Decisions for Investors

• Given the strong earnings beat, upward guidance revision, and multiple positive analyst ratings, investors could view AbbVie as a solid growth holding within the pharmaceutical sector, well-positioned to manage the decline of its Humira franchise.
• Monitor the sales trajectory of key growth drivers Skyrizi, Rinvoq, and Vraylar, as their continued outperformance is critical to the investment thesis and the company's ability to potentially raise long-term guidance in 2026.
• Keep the early 2025 phase 1 data read-out for the DACRA asset, ABBV-295, on the radar as a potential near-term catalyst that is not yet fully priced into the stock according to analyst commentary.